{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:58:07Z","timestamp":1792267087464,"version":"4.4.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2024-00395863"],"award-info":[{"award-number":["RS-2024-00395863"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2023R1A6C101A009"],"award-info":[{"award-number":["2023R1A6C101A009"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C301016611"],"award-info":[{"award-number":["2021R1A2C301016611"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1I1A1A01071162"],"award-info":[{"award-number":["2022R1I1A1A01071162"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113711","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T15:21:01Z","timestamp":1744730461000},"page":"113711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Potent therapeutic efficacy of intranasally deliverable paclitaxel modified with pH-sensitive and PEGylated polymeric micelle against glioblastoma"],"prefix":"10.1016","volume":"382","author":[{"given":"Young-Beom","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayananda","family":"Kasala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinWoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Rum","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Ok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.jconrel.2025.113711_bb0005","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.2174\/0929867324666170516123206","article-title":"Glioblastoma multiforme, diagnosis and treatment; Recent literature review","volume":"24","author":"Batash","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113711_bb0010","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.15252\/emmm.201302627","article-title":"Emerging treatment strategies for glioblastoma multiforme","volume":"6","author":"Carlsson","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113711_bb0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/erm.12.30","article-title":"The cellular origin for malignant glioma and prospects for clinical advancements","volume":"12","author":"Zong","year":"2012","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.jconrel.2025.113711_bb0020","series-title":"Cell of Origin for Malignant Gliomas and its Implication in Therapeutic Development","volume":"7(5)","author":"Zong","year":"2015"},{"issue":"Supplement_5","key":"10.1016\/j.jconrel.2025.113711_bb0025","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jconrel.2025.113711_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000209467","article-title":"Frontiers of neurology and neuroscience. Clinical trials in the neurosciences. Introduction","volume":"25","author":"Coull","year":"2009","journal-title":"Front. Neurol. Neurosci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-006-9303-1","article-title":"Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience","volume":"83","author":"Lawson","year":"2007","journal-title":"J. Neurooncol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0040","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix","year":"2001","journal-title":"J. Neurosurg."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113711_bb0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113711_bb0050","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113711_bb0055","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2217\/fon.10.123","article-title":"Improving the radiosensitivity of radioresistant and hypoxic glioblastoma","volume":"6","author":"Sheehan","year":"2010","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0060","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3892\/ol.2017.6251","article-title":"Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine","volume":"14","author":"Wenger","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jconrel.2025.113711_bb0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fonc.2015.00259","article-title":"CDK4\/6 inhibitor PD0332991 in glioblastoma treatment: does it have a future?","volume":"5","author":"Schroder","year":"2015","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0070","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","article-title":"Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma","volume":"140","author":"Taylor","year":"2018","journal-title":"J. Neurooncol."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113711_bb0075","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noq025","article-title":"Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (north American brain tumor consortium study 06-02)","volume":"12","author":"Iwamoto","year":"2010","journal-title":"Neuro Oncol."},{"issue":"79","key":"10.1016\/j.jconrel.2025.113711_bb0080","doi-asserted-by":"crossref","first-page":"34935","DOI":"10.18632\/oncotarget.26183","article-title":"Aldoxorubicin and Temozolomide combination in a xenograft mice model of human glioblastoma","volume":"9","author":"Da Ros","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113711_bb0085","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00432-016-2161-0","article-title":"Phase I trial of dovitinib (TKI258) in recurrent glioblastoma","volume":"142","author":"Schafer","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0090","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-019-03236-6","article-title":"Phase II study of Dovitinib in recurrent glioblastoma","volume":"144","author":"Sharma","year":"2019","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1248\/cpb.56.70","article-title":"Paclitaxel solubility in aqueous dispersions and mixed micellar solutions of lecithin","volume":"56","author":"Sznitowska","year":"2008","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.jconrel.2025.113711_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/bs.apha.2014.06.002","article-title":"Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances","volume":"71","author":"Doolittle","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.113711_bb0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","author":"Perez-Herrero","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030324","article-title":"Current FDA-approved therapies for high-grade malignant gliomas","volume":"9","author":"Fisher","year":"2021","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.jconrel.2025.113711_bb0115","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41587-024-02408-8","volume":"42","author":"FDA approves first IDH-targeted glioma drug","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-23-1503","article-title":"FDA approval summary: Dabrafenib in combination with Trametinib for BRAFV600E mutation-positive low-grade glioma","volume":"30","author":"Barbato","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113711_bb0125","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1158\/1535-7163.MCT-10-0552","article-title":"Paclitaxel-dependent cell lines reveal a novel drug activity","volume":"9","author":"Ganguly","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113711_bb0130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.113711_bb0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2017.08.035","article-title":"Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus","volume":"145","author":"Kasala","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113711_bb0140","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3687700","article-title":"Paclitaxel: application in modern oncology and nanomedicine-based Cancer therapy","volume":"2021","author":"Sharifi-Rad","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.jconrel.2025.113711_bb0145","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.2147\/IJN.S136401","article-title":"Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts","volume":"12","author":"Shen","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.jconrel.2025.113711_bb0150","article-title":"Targeted and effective glioblastoma therapy via aptamer-modified tetrahedral framework nucleic acid-paclitaxel nanoconjugates that can pass the blood brain barrier","volume":"21","author":"Shi","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.113711_bb0155","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.2147\/IJN.S165184","article-title":"Magnetic targeting of paclitaxel-loaded poly(lactic-co-glycolic acid)-based nanoparticles for the treatment of glioblastoma","volume":"13","author":"Ganipineni","year":"2018","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13046-023-02843-6","article-title":"Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis","volume":"42","author":"Qu","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0165","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2305308","article-title":"Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and\/or paclitaxel","volume":"55","author":"Ahmed","year":"2023","journal-title":"Ann. Med."},{"issue":"18","key":"10.1016\/j.jconrel.2025.113711_bb0170","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2204621120","article-title":"Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0175","article-title":"Improved Antiglioblastoma activity and BBB permeability by conjugation of paclitaxel to a cell-penetrative MMP-2-cleavable peptide","volume":"8","author":"Hua","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"issue":"13","key":"10.1016\/j.jconrel.2025.113711_bb0180","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.2174\/1389450119666180131105822","article-title":"Nanocarrier based advances in drug delivery to tumor: an overview","volume":"19","author":"Jain","year":"2018","journal-title":"Curr. Drug Targets"},{"issue":"9","key":"10.1016\/j.jconrel.2025.113711_bb0185","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2217\/nnm.16.9","article-title":"Recent advances in liposome surface modification for oral drug delivery","volume":"11","author":"Nguyen","year":"2016","journal-title":"Nanomedicine (Lond.)"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2025.113711_bb0190","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.01.067","article-title":"Protein-based nanoparticles: from preparation to encapsulation of active molecules","volume":"522","author":"Tarhini","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2025.113711_bb0195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.colsurfb.2018.08.057","article-title":"Recent insights into the development of nucleic acid-based nanoparticles for tumor-targeted drug delivery","volume":"172","author":"Buddolla","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"19","key":"10.1016\/j.jconrel.2025.113711_bb0200","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.2174\/1381612822666160217125028","article-title":"Polymer-based drug delivery systems, development and pre-clinical status","volume":"22","author":"Jaimes-Aguirre","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2025.113711_bb0205","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S146315","article-title":"Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors","volume":"12","author":"Din","year":"2017","journal-title":"Int. J. Nanomed."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113711_bb0210","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2468-1253(24)00197-3","article-title":"Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial","volume":"9","author":"Dorman","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0215","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1186\/s12885-024-12936-w","article-title":"Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine\/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol","volume":"24","author":"Budillon","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2025.113711_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104151","article-title":"Phase I study of intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for unresectable peritoneal metastases","volume":"82","author":"Ceelen","year":"2022","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113711_bb0225","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.4143\/crt.2022.1436","article-title":"Safety and tolerability of weekly Genexol-PM, a Cremophor-free polymeric micelle formulation of paclitaxel, with carboplatin in gynecologic Cancer: a phase I study","volume":"55","author":"Nam","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0230","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1158\/1078-0432.CCR-19-2182","article-title":"Ultrasound-mediated delivery of paclitaxel for glioma: a comparative study of distribution, toxicity, and efficacy of albumin-bound versus Cremophor formulations","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113711_bb0235","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4037\/ccn2018836","article-title":"The intranasal route as an alternative method of medication administration","volume":"38","author":"Tucker","year":"2018","journal-title":"Crit. Care Nurse"},{"key":"10.1016\/j.jconrel.2025.113711_bb0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Erdo","year":"2018","journal-title":"Brain Res. Bull."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113711_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091870","article-title":"Nose-to-brain delivery of therapeutic peptides as nasal aerosols","volume":"14","author":"Alabsi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113711_bb0250","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113711_bb0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113711_bb0260","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4103\/0250-474X.164770","article-title":"Smart polymers in nasal drug delivery","volume":"77","author":"Chonkar","year":"2015","journal-title":"Indian J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113711_bb0265","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mabi.201000388","article-title":"Advances in Mucoadhesion and Mucoadhesive polymers","volume":"11","author":"Khutoryanskiy","year":"2011","journal-title":"Macromol. Biosci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0270","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bpj.2011.08.058","article-title":"Distribution of sialic acids on mucins and gels: a defense mechanism","volume":"102","author":"Baos","year":"2012","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2025.113711_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114575","article-title":"Functionalisation of chitosan with methacryloyl and crotonoyl groups as a strategy to enhance its mucoadhesive properties","volume":"205","author":"Vanukuru","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2025.113711_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.159770","article-title":"Potent antitumor effect of intranasally administrable pH-sensitive and photothermal polymeric oncolytic adenovirus for the treatment of brain cancer","volume":"505","author":"Zhao","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.jconrel.2025.113711_bb0285","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2014.11.021","article-title":"Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus","volume":"41","author":"Moon","year":"2015","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030597","article-title":"A pH- and bioreducible cationic copolymer with amino acids and Piperazines for adenovirus delivery","volume":"14","author":"Thambi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0295","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jcis.2010.04.090","article-title":"Folate mediated in vitro targeting of depolymerised trimethylated chitosan having arginine functionality","volume":"348","author":"Morris","year":"2010","journal-title":"J. Colloid Interface Sci."},{"issue":"33","key":"10.1016\/j.jconrel.2025.113711_bb0300","doi-asserted-by":"crossref","first-page":"8759","DOI":"10.1016\/j.biomaterials.2010.07.073","article-title":"Enhanced in-vitro transfection and biocompatibility of L-arginine modified oligo (\u2212alkylaminosiloxanes)-graft-polyethylenimine","volume":"31","author":"Morris","year":"2010","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0305","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.biomaterials.2011.09.025","article-title":"A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy","volume":"33","author":"Shan","year":"2012","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0310","first-page":"29","article-title":"Jain* spectrophotometric estimation of paclitaxel","volume":"2","author":"Prashant Kesarwani","year":"2011","journal-title":"Int. J. Adv. Pharm. Sci."},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2025.113711_bb0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1024866504538","article-title":"Towards predictive models of stem cell fate","volume":"41","author":"Viswanathan","year":"2003","journal-title":"Cytotechnology"},{"key":"10.1016\/j.jconrel.2025.113711_bb0320","series-title":"Multiprotein Complexes. Methods and Protocols","first-page":"243","article-title":"Optimization of sample preparation for the observation of macromolecular complexes by Electron (cryo-)microscopy","author":"Frechard","year":"2021"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0325","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11051-018-4447-4","article-title":"pH-responsive polymeric micelles with tunable aggregation-induced emission and controllable drug release","volume":"21","author":"Dai","year":"2018","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2025.113711_bb0330","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/340315","article-title":"Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs","volume":"2013","author":"Xu","year":"2013","journal-title":"J. Drug Deliv."},{"issue":"17","key":"10.1016\/j.jconrel.2025.113711_bb0335","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.biomaterials.2009.03.006","article-title":"Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect","volume":"30","author":"Wiradharma","year":"2009","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113711_bb0340","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2174\/1567201811666140609154949","article-title":"Paclitaxel formulations: challenges and novel delivery options","volume":"11","author":"Nehate","year":"2014","journal-title":"Curr. Drug Deliv."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0345","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5468\/ogs.2018.61.3.421","article-title":"Non-convulsive seizure related to Cremophor EL-free, polymeric micelle formulation of paclitaxel: a case report","volume":"61","author":"Shin","year":"2018","journal-title":"Obstet. Gynecol. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113711_bb0350","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/17425247.2013.821978","article-title":"pH- and ion-sensitive polymers for drug delivery","volume":"10","author":"Yoshida","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0355","doi-asserted-by":"crossref","first-page":"71","DOI":"10.37349\/etat.2020.00005","article-title":"The impact of tumour pH on cancer progression: strategies for clinical intervention","volume":"1","author":"Ward","year":"2020","journal-title":"Explor. Target Antitumor. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113711_bb0360","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.apsb.2021.01.012","article-title":"The reversed intra- and extracellular pH in tumors as a unified strategy to chemotherapeutic delivery using targeted nanocarriers","volume":"11","author":"P\u00e9rez-Herrero","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113711_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043390","article-title":"Biomaterials-enhanced intranasal delivery of drugs as a direct route for brain targeting","volume":"24","author":"Marcello","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0370","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jps.21031","article-title":"Evaluation of human nasal RPMI 2650 cells grown at an air\u2013liquid interface as a model for nasal drug transport studies","volume":"97","author":"Bai","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113711_bb0375","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s11095-016-1975-4","article-title":"An assessment of the permeation enhancer, 1-phenyl-piperazine (PPZ), on Paracellular flux across rat intestinal mucosae in Ussing chambers","volume":"33","author":"Bzik","year":"2016","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113711_bb0380","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s11095-007-9488-9","article-title":"Safe and effective permeation enhancers for oral drug delivery","volume":"25","author":"Whitehead","year":"2008","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0385","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/acs.molpharmaceut.5b00803","article-title":"The pH of Piperazine derivative solutions predicts their utility as Transepithelial permeation enhancers","volume":"13","author":"Lamson","year":"2016","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0390","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s10989-019-09971-8","article-title":"Intranasal drug delivery into mouse nasal mucosa and brain utilizing arginine-rich cell-penetrating peptide-mediated protein transduction","volume":"26","author":"Miwa","year":"2020","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0395","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2017.07.077","article-title":"Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide","volume":"530","author":"Kanazawa","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113711_bb0400","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1007\/s13346-020-00816-2","article-title":"Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating","volume":"10","author":"de Oliveira Junior","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/ph11010009","article-title":"Improved intranasal Retentivity and Transnasal absorption enhancement by PEGylated poly-l-ornithine","volume":"11","author":"Kamiya","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2025.113711_bb0410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2022.03.017","article-title":"Nose-to-brain\/spinal cord delivery kinetics of liposomes with different surface properties","volume":"344","author":"Kurano","year":"2022","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113711_bb0415","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1021\/bm100522c","article-title":"Effect of PEGylation on the toxicity and permeability enhancement of chitosan","volume":"11","author":"Casettari","year":"2010","journal-title":"Biomacromolecules"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113711_bb0420","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.1995.13.8.2066","article-title":"Salvage chemotherapy with paclitaxel for recurrent primary brain tumors","volume":"13","author":"Chamberlain","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113711_bb0425","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.1997.15.9.3121","article-title":"Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous system consortium","volume":"15","author":"Fetell","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0430","first-page":"427","article-title":"Brain targeted delivery of paclitaxel using endogenous ligand","volume":"11","author":"Acharya","year":"2016","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2025.113711_bb0435","article-title":"Research progress in brain-targeted nasal drug delivery","volume":"15","author":"Huang","year":"2023","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0445","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1767","article-title":"Direct nose to the brain nanomedicine delivery presents a formidable challenge","volume":"14","author":"Yokel","year":"2022","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113711_bb0450","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/jcbfm.2014.215","article-title":"Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration","volume":"35","author":"Lochhead","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0455","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41598-019-39191-5","article-title":"Distribution of insulin in trigeminal nerve and brain after intranasal administration","volume":"9","author":"Lochhead","year":"2019","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113711_bb0460","first-page":"2112","article-title":"Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL","volume":"56","author":"Sparreboom","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113711_bb0465","first-page":"165","article-title":"Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans","volume":"10","author":"Li","year":"2018","journal-title":"Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113711_bb0470","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","article-title":"Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine","volume":"94","author":"Sparreboom","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113711_bb0475","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ijc.1591","article-title":"Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells","volume":"97","author":"Tan","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113711_bb0480","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.neo.7900122","article-title":"Cisplatinum and Taxol induce different patterns of p53 phosphorylation","volume":"3","author":"Damia","year":"2001","journal-title":"Neoplasia"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:55:39Z","timestamp":1777870539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925003311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":96,"alternative-id":["S0168365925003311"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113711","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent therapeutic efficacy of intranasally deliverable paclitaxel modified with pH-sensitive and PEGylated polymeric micelle against glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113711"}}